In a new study of more than 40,000 patients, researchers at Intermountain Health in Salt Lake City have found that patients who have no evidence of calcium in ...

Holy Cross Medical Center is expanding heart care for northern New Mexico residents with the introduction of HeartFlow Plaque Analysis, an advanced, non-invasive technology that helps doctors better u ...

Recent developments in reimbursement and insurer coverage for plaque analysis in the US are a step towards the evaluative ...

Which patients with a history of myocardial infarction (MI) are at risk of having another? The tools to predict risk for recurrent cardiac events in patients with established coronary artery disease ...

More than half of people living with HIV and suppressed viral loads nonetheless had imaging-confirmed coronary artery disease — and despite longtime use of HIV drugs that have been associated with ...

Elucid today announced that, effective January 1, 2026, its Plaque-IQ(TM) coronary plaque analysis has received a new Category I Current Procedural Terminology (CPT(R)) designation, alongside ...

Please provide your email address to receive an email when new articles are posted on . The virus that causes COVID-19 may expedite progression of coronary lesions to high-risk plaque. SARS-CoV-2 was ...

Coverage unlocks reimbursable AI plaque quantification, advancing coronary risk assessment in everyday cardiology ...

For years, many men have assumed that heart attacks are a problem for their 50s or 60s. New research upends that timeline, ...

Scientists have designed an immunotherapy that reduces plaque in the arteries of mice, presenting a possible new treatment strategy against heart disease. The antibody-based therapy could complement ...

Quantitative coronary plaque analysis, such as Elucid’s Plaque-IQ™, is now reportable under Category I CPT code 75577, with a national average payment amount of $1,012 for use in imaging centers and ...